Avedro Raises $25 Million to Advance Cross-linking Technology

May 4, 2018: By Joan McKenna

Avedro announced May 2 that it secured $25 million in financing to invest in product development, clinical studies, and commercial efforts for its cross-linking technology. The drug and device combination treatment is labeled to treat keratoconus and corneal ectasia.

The financing was led by Lilly Asia Ventures, with major participation from existing investors OrbiMed Advisors, InterWest Partners, and HealthQuest Capital.

Avedro, of Waltham, Massachusetts, noted that Lilly Asia Ventures’ expertise in Asian markets would be invaluable as Avedro expands its product portfolio and global reach.

In March, Avedro announced that the US FDA had agreed to the design and size of its pivotal Phase III clinical trial for an epithelium-on (epi-on) corneal collagen cross-linking procedure for progressive keratoconus. The technology’s current US labeling is for an epi-off procedure.

In addition, Avedro is developing photorefractive intrastromal corneal collagen cross-linking, or PiXL, for non-invasive treatment of low myopia.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023